Literature DB >> 10525669

Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin.

M Hamilton-Wessler1, M Ader, M Dea, D Moore, P N Jorgensen, J Markussen, R N Bergman.   

Abstract

AIMS/HYPOTHESIS: The provision of stable, reproducible basal insulin is crucial to diabetes management. This study in dogs examined the metabolic effects and interstitial fluid (ISF) profiles of fatty acid acylated insulin, Lys(B29)-tetradecanoyl, des-(B30) human insulin (NN304).
METHODS: Euglycaemic clamps were carried out under inhalant anaesthesia during equimolar intravenous infusions (3.6 pmol. min(-1) x kg(-1) for 480 min) of human insulin or NN304 (n = 8 per group).
RESULTS: Steady-state total NN304 (albumin-bound and unbound) was considerably higher in plasma compared with human insulin (1895 +/- 127 vs 181 +/- 10 pmol/l, p < 0.001) and increased in interstitial fluid (163 +/- 14 vs 106 +/- 9 pmol/l, p < 0.01). The halftime for appearance of NN304 in interstitial fluid was slower than human insulin (92 vs 29 min, p < 0.001). Yet, equivalency of action was shown for glucose turnover; steady-state glucose uptake (Rd) of 7.28 +/- 0.55 and 6.76 +/- 0.24 mg. min(-1). kg(-1) and endogenous glucose production of 0.11 +/- 0.12 and 0.22 +/- 0.03 mg x min(-1) x kg(-1) (p > 0.40; NN304 and human insulin, respectively). Similar to interstitial fluid, half times for Rd and endogenous glucose production were delayed during NN304 infusion (162 vs 46 min and 80 vs 31 min, respectively; p < 0.01 vs human insulin). CONCLUSION/
INTERPRETATION: Firstly equivalency of steady-state action is found at equimolar physiologic infusions of human insulin and NN304. Secondly NN304 binding to plasma albumin results in slower NN304 appearance in the interstitial compartment compared with human insulin. Thirdly the delay in appearance of NN304 in interstitial fluid may not in itself be a source of the protracted action of this insulin analogue. The protracted effect is due primarily to albumin binding of the insulin analogue NN304. [Diabetologia (1999) 42: 1254-1263]

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525669     DOI: 10.1007/s001250051301

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

Review 1.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

2.  Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

Authors:  Fariba Shojaee-Moradie; Michelle P Y Chan; Micayla A Telfer; Dietrich Brandenburg; Erik Sundermann; Heike Eckey; Jens Kleinjung; Achim Schüttler; Richard H Jones
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

3.  Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.

Authors:  Yang Liu; Juneyoung Lee; Kathryn M Mansfield; Jeong Hoon Ko; Sahar Sallam; Chrys Wesdemiotis; Heather D Maynard
Journal:  Bioconjug Chem       Date:  2017-01-03       Impact factor: 4.774

4.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

Review 5.  Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

7.  Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations.

Authors:  Eldon D Lehmann; Cristina Tarín; Jorge Bondia; Edgar Teufel; Tibor Deutsch
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 8.  Insulin detemir: a review of its use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

9.  Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.

Authors:  Thorsten Hartmann; Sabrina Overhagen; D Margriet Ouwens; Silja Raschke; Paulus Wohlfart; Norbert Tennagels; Nina Wronkowitz; Jürgen Eckel
Journal:  Cardiovasc Diabetol       Date:  2016-07-15       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.